Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes-Reference-Cited by-同舟云学术

Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes

Author:

Natale Patrizia¹²³,Palmer Suetonia C⁴,Tunnicliffe David J¹,Toyama Tadashi⁵⁶,Strippoli Giovanni FM²⁷⁸

Affiliation:

1. Sydney School of Public Health; The University of Sydney; Sydney Australia

2. Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J); University of Bari Aldo Moro; Bari Italy

3. Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences; University of Foggia; Foggia Italy

4. Department of Medicine; University of Otago Christchurch; Christchurch New Zealand

5. Department of Nephrology; Kanazawa University; Kanazawa Japan

6. Innovative Clinical Research Center; Kanazawa University; Kanazawa Japan

7. Nephrology, Dialysis and Transplantation Unit; Department of Medical and Surgical Sciences, University of Foggia; Foggia Italy

8. Cochrane Kidney and Transplant, Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Reference41 articles.

1. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022;Diabetes Care,2022

2. ANZDATA 41st Annual Report 2018 (Data to 2017) https://www.anzdata.org.au/report/anzdata-41st-annual-report-2018-anzdata/